Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Moderna, Inc. (MRNA) had Stock-Based Compensation of $429.00M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$3.24B |
|
$-3.56B |
|
$1.46B |
|
$1.77B |
|
$7.18B |
|
$-3.94B |
|
$338.00M |
|
$-3.61B |
|
$-3.61B |
|
$-3.56B |
|
$-3.56B |
|
$-3.56B |
|
$-3.56B |
|
$-3.94B |
|
$-3.85B |
|
384.00M |
|
384.00M |
|
$-9.28 |
|
$-9.28 |
|
| Balance Sheet Financials | |
$8.10B |
|
$2.20B |
|
$6.04B |
|
$14.14B |
|
$2.21B |
|
$39.00M |
|
$1.03B |
|
$3.24B |
|
$10.90B |
|
$10.90B |
|
$10.90B |
|
-- |
|
| Cash Flow Statement Financials | |
$-3.00B |
|
$1.95B |
|
$56.00M |
|
$2.93B |
|
$1.93B |
|
$-999.00M |
|
|
Stock-Based Compensation |
$429.00M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|